LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Orforglipron, an oral GLP-1, reduced HbA1c more than ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some ...

FRIDAY, Oct. 31, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax ...

FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly's experimental ...

Veterinary teams enhance feline diabetes management through personalized care, effective communication, and evolving treatment options for improved quality of life.

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...